Navigation Links
Sunesis Pharmaceuticals Presents Updated Clinical Data From Ongoing Phase 2 Trial of Voreloxin (Formerly SNS-595) in Ovarian Cancer Patients at the 44th ASCO Annual Meeting
Date:5/31/2008

se for 90 days or more or a complete or partial response. The preliminary median Progression Free Survival was 91 days, or 13 weeks, at the 48 mg/m(2) dose; twenty-three patients treated at this dose remained on study as of May 12, 2008.

All patients enrolled in the trial have previously failed treatment with platinum-containing regimens, and 26 patients have also failed prior treatment with doxorubicin HCl liposome injection (Doxil(R)). Both platinum-resistant and Doxil-resistant patients in the Phase 2 clinical trial have responded to voreloxin therapy.

In March, based on the indications of clinical activity and the acceptable tolerability profile demonstrated in this Phase 2 clinical trial, Sunesis increased the dose of voreloxin in this trial to 60 mg/m(2) once every 28 days. Thirty-four patients have been enrolled at the 60 mg/m(2) dose level. To date, with an initial eight patients evaluable for efficacy response, one patient has achieved a partial response.

Voreloxin has been well-tolerated in the platinum-resistant ovarian cancer population. With 65 patients evaluable for safety at the 48 mg/m(2) dose and 20 patients evaluable for safety at the 60 mg/m(2) dose, low rates of febrile neutropenia (<10%) or other Grade 3-4 adverse events (fatigue (12%), vomiting (5%) and infections (5% )) have been observed. Based on voreloxin's safety profile, Sunesis recently announced that the protocol for the ongoing Phase 2 clinical trial was amended to increase the dose by 25 percent to 75 mg/m(2) given once every 28 days. Sunesis expects to enroll approximately 30 patients at this new dose level by the end of this year.

"Voreloxin has demonstrated promising clinical activity and tolerability among platinum-resistant ovarian cancer patients and we are focused on advancing this compound in this indication toward late-stage trials," said Daniel Swisher, Sunesis' Chief Executive Officer. "We are pleased by the rapid progress of enrollment of vorelo
'/>"/>

SOURCE Sunesis Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Sunesis Pharmaceuticals to Present Interim Clinical Data From Voreloxin (Formerly SNS-595) Ovarian Cancer Trial at 44th ASCO Annual Meeting and Acute Myeloid Leukemia Trials at 13th EHA Congress
2. Sunesis Pharmaceuticals Initiates Phase 2 Clinical Trial of Voreloxin (SNS-595) in Acute Myeloid Leukemia
3. Sunesis Pharmaceuticals Reports Data from Nonclinical Studies of SNS-032 at the Annual Meeting of the American Association for Cancer Research
4. Sunesis Pharmaceuticals to Present Non-Clinical Data at the Annual Meeting of the American Association for Cancer Research
5. Sunesis Pharmaceuticals Reports Positive Interim Data for SNS-595 Single-Agent Activity in Platinum-Resistant Ovarian Cancer
6. Sunesis Pharmaceuticals to Present Data on Two Product Candidates at the 49th Annual Meeting of the American Society of Hematology
7. Sunesis Pharmaceuticals Reports Preliminary SNS-595 Activity in Ovarian Cancer Clinical Trial at AACR-NCI-EORTC International Conference
8. Sunesis Pharmaceuticals Commences Clinical Trials of SNS-595 and SNS-314
9. Vion Pharmaceuticals to Present Clinical Data on Cloretazine(R) (VNP40101M) at the ASCO(R) Annual Meeting
10. Strativa Pharmaceuticals Announces Preliminary Results from ONCONASE(R) Phase IIIb Clinical Trial
11. Access Pharmaceuticals Presents Favorable Ovarian Cancer Data and Clinical Update on ProLindac(TM) Development at Prestigious International Symposium
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... 2014  BC Technical, the nation,s leading non-OEM provider ... a leader in sales, service and installation of GE ... Technical to continue to expand their resources and inventory ... modalities. "We are committed to driving ... , president and CEO of BC Technical. "We set ...
(Date:8/29/2014)... 29, 2014 Research and Markets  has announced ... Insight 2014" report to their offering. ... one of the largest segments of pharmaceuticals industry. The numbers ... the available therapies were unable to meet the market requirements. ... for CNS disorder, especially over the past two decades. The ...
(Date:8/29/2014)... DUBLIN , Aug. 29, 2014 ... the "Research and Development Trend Forecast of Pharmaceutical ... offering. Research and Development Trend Forecast ... , 2014-2018 mainly analyzes China,s ... status, supply & demand, competition landscape, and business performance ...
Breaking Medicine Technology:BC Technical Acquires Polaris Medical Imaging 2US CNS Disorders Drug Pipeline Insight 2014 2Research and Development Trend Forecast of Pharmaceutical Equipment Market in China, 2014-2018 2
... Pharmaceuticals, Inc., a publicly held corporation, (Symbol: PDRX.PK) ... an electronic medical record, from Wilson Medical Software, ... quality, low-cost tool for physicians to maintain patient ... and assistants to rapidly record visit notes and ...
... Today,s U.S. Supreme Court decision in Pliva v. ... generic drug companies legal immunity when they ignore harmful side-effects ... eliminates any incentive for generic manufacturers to ensure their drug ... dangers. This decision also means that brand-name manufacturers ...
Cached Medicine Technology:PD-Rx Pharmaceuticals Acquires Wilson Medical's EMR 2Generic Drug Decision Disastrous to Patient Safety 2
(Date:8/29/2014)... August 29, 2014 According to new research ... Not Peer Pressure, Key to Prescription Drug Misuse Among Young ... focus for 18-29 year olds when it comes to prescription ... for this age group the real problem which influences misuse ... associations and recreational use of them to have fun with ...
(Date:8/29/2014)... Market Research Report on Global ... professional and in-depth market survey on Global and ... the basic information of Glass microfiber including its ... explores global and China’s top manufacturers of Glass ... and market share etc. , The report further ...
(Date:8/29/2014)... Mirada, CA (PRWEB) August 29, 2014 ... which will give patients the convenience of visiting ... with Healthpointe doctors through telemedicine. , Healthpointe doctors are ... calls (or audio). If necessary, the doctor can even ... assessed the patient’s condition, he or she can prescribe ...
(Date:8/29/2014)... 2014 Healthpointe is pleased to ... Therapy students via Clinical Rotations. Physical ... shadowing Healthpointe providers and specialists throughout their daily ... clinical experience and learn professional preparation. ... insight into several patient care techniques and expand ...
(Date:8/29/2014)... CA (PRWEB) August 29, 2014 Healthpointe ... J. Chuang, has joined their practice. Dr. Chuang garners ... and specializes in minimally-invasive arthroscopic and reconstructive treatments of ... care for patients with general and sports-related orthopedic needs. ... in the medical field. As an Orange County native, ...
Breaking Medicine News(10 mins):Health News:Peer Pressure Irrelevant in Prescription Drug Abuse for Young Adults 2Health News:Peer Pressure Irrelevant in Prescription Drug Abuse for Young Adults 3Health News:Global and Chinese Glass Microfiber Industry Forecasts to 2019 in New Research Report Available at ReportsnReports.com 2Health News:Global and Chinese Glass Microfiber Industry Forecasts to 2019 in New Research Report Available at ReportsnReports.com 3Health News:Global and Chinese Glass Microfiber Industry Forecasts to 2019 in New Research Report Available at ReportsnReports.com 4Health News:Virtual Doctor’s Appointments Now Available at Healthpointe 2Health News:Healthpointe is Now Offering Clinical Rotations for Chapman University Physical Therapy Students 2Health News:Healthpointe is Honored to Induct Orthopedic Surgeon into Their Team 2
... HealthDay Reporter , WEDNESDAY, Aug. 25 (HealthDay News) -- If you,re ... recall due to salmonella contamination has probably made you refrain from ... now some time has passed, and you,re starting to crave an ... languishing in your fridge or are you inviting a bout of ...
... HealthDay Reporter , WEDNESDAY, Aug. 25 (HealthDay News) -- ... caloric overindulgence can be easily worked off at the gym, ... a month,s worth of unhealthy living changes physiology, making piled-on ... [over-eating] can have later long-term effects," said study co-author Dr. ...
... in seven patients experience more pain, physical and emotional problems ... quarter have less vitality. Those are the key findings of ... by the British Journal of Surgery . ... men with an average age of 54, who had undergone ...
... TUESDAY, Aug. 24 (HealthDay News) -- A new study finds ... the glucose-lowering diabetes drugs Avandia and Actos are about the ... studies that found that the risk was elevated for Avandia ... in line with some other previous studies, further muddying the ...
... room waiting times could be cut by over one third ... a new approach to the triage process of sorting ... in the International Journal of Six Sigma and Competitive ... University in Zarqa, Jordan and colleagues have turned to a ...
... HealthDay Reporter , TUESDAY, Aug. 24 (HealthDay ... the herpes virus should not worry that their use ... than 1 percent of women develop herpes simplex during ... during pregnancy of antiviral drugs such as acyclovir (Zovirax), ...
Cached Medicine News:Health News:Are The Eggs in Your Fridge Safe to Eat? 2Health News:Are The Eggs in Your Fridge Safe to Eat? 3Health News:Are The Eggs in Your Fridge Safe to Eat? 4Health News:Short-Term Overeating Could Make Long-Term Weight Loss Tougher 2Health News:Up to 1 in 4 patients report more physical problems a year after surgery than before 2Health News:Heart Risks the Same With 2 Diabetes Drugs: Study 2Health News:Heart Risks the Same With 2 Diabetes Drugs: Study 3Health News:Engineering shorter wait times in the ER 2Health News:Herpes Drugs Won't Raise Birth Defect Risk, Study Finds 2Health News:Herpes Drugs Won't Raise Birth Defect Risk, Study Finds 3
... Medical Records (including ExamDRAW) is the most ... the industry. Doctors and staff can fully ... and accuracy using our trademarked pre-written menus ... typing, we have created the fastest, easiest-to-use ...
... The DiaScreen 50 Urine Chemistry Analyzer is ... Urinalysis. It saves time for technicians, allowing them ... computing test results. It has a throughput of ... of 200 test results, which may be downloaded ...
... III represents the latest in advanced cement bowl ... types of bone cement safely and thoroughly. ... the blades scrape the bowl whether mixing with ... , ,The new bowl design optimizes ...
... DePuy developed the ULTRAMIX Vacuum Mixing ... high-performance cements and achieve optimum strength. , ... an "environmentally friendly" design that protects the ... during loading and mixing. The unique offset ...
Medicine Products: